Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Andersen, CL, Bjørn, ME, McMullin, MF, Harrison, C, Samuelsson, J, Ejerblad, E, Zweegman, S, Fernandes, S, Bareford, D, Knapper, S, Löfvenberg, E, Linder, O, Andreasson, B, Ahlstrand, E, Jensen, MK, Bjerrum, OW, Vestergaard, H, Larsen, H, Klausen, TW, Mourits-Andersen, T, Skov, V, Thomassen, M, Kruse, T, Grønbæk, K & Hasselbalch, HC 2014, 'Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat' Leukemia Research, vol. 38, no. 7, pp. 816-21. https://doi.org/10.1016/j.leukres.2014.04.002

APA

Andersen, C. L., Bjørn, M. E., McMullin, M. F., Harrison, C., Samuelsson, J., Ejerblad, E., ... Hasselbalch, H. C. (2014). Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research, 38(7), 816-21. https://doi.org/10.1016/j.leukres.2014.04.002

CBE

Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. 2014. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research. 38(7):816-21. https://doi.org/10.1016/j.leukres.2014.04.002

MLA

Vancouver

Author

Andersen, Christen Lykkegaard ; Bjørn, Mads Emil ; McMullin, Mary Frances ; Harrison, Claire ; Samuelsson, Jan ; Ejerblad, Elisabeth ; Zweegman, Sonja ; Fernandes, Savio ; Bareford, David ; Knapper, Steven ; Löfvenberg, Eva ; Linder, Olle ; Andreasson, Bjørn ; Ahlstrand, Erik ; Jensen, Morten Krogh ; Bjerrum, Ole Weis ; Vestergaard, Hanne ; Larsen, Herdis ; Klausen, Tobias Wirenfeldt ; Mourits-Andersen, Torben ; Skov, Vibe ; Thomassen, Mads ; Kruse, Torben ; Grønbæk, Kirsten ; Hasselbalch, Hans Carl. / Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. In: Leukemia Research. 2014 ; Vol. 38, No. 7. pp. 816-21.

Bibtex

@article{1a71f26b66a744419e496dc30dfa308b,
title = "Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat",
abstract = "YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.",
author = "Andersen, {Christen Lykkegaard} and Bj{\o}rn, {Mads Emil} and McMullin, {Mary Frances} and Claire Harrison and Jan Samuelsson and Elisabeth Ejerblad and Sonja Zweegman and Savio Fernandes and David Bareford and Steven Knapper and Eva L{\"o}fvenberg and Olle Linder and Bj{\o}rn Andreasson and Erik Ahlstrand and Jensen, {Morten Krogh} and Bjerrum, {Ole Weis} and Hanne Vestergaard and Herdis Larsen and Klausen, {Tobias Wirenfeldt} and Torben Mourits-Andersen and Vibe Skov and Mads Thomassen and Torben Kruse and Kirsten Gr{\o}nb{\ae}k and Hasselbalch, {Hans Carl}",
note = "Copyright {\circledC} 2014 Elsevier Ltd. All rights reserved.",
year = "2014",
month = "7",
doi = "10.1016/j.leukres.2014.04.002",
language = "English",
volume = "38",
pages = "816--21",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Pergamon",
number = "7",

}

RIS

TY - JOUR

T1 - Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

AU - Andersen, Christen Lykkegaard

AU - Bjørn, Mads Emil

AU - McMullin, Mary Frances

AU - Harrison, Claire

AU - Samuelsson, Jan

AU - Ejerblad, Elisabeth

AU - Zweegman, Sonja

AU - Fernandes, Savio

AU - Bareford, David

AU - Knapper, Steven

AU - Löfvenberg, Eva

AU - Linder, Olle

AU - Andreasson, Bjørn

AU - Ahlstrand, Erik

AU - Jensen, Morten Krogh

AU - Bjerrum, Ole Weis

AU - Vestergaard, Hanne

AU - Larsen, Herdis

AU - Klausen, Tobias Wirenfeldt

AU - Mourits-Andersen, Torben

AU - Skov, Vibe

AU - Thomassen, Mads

AU - Kruse, Torben

AU - Grønbæk, Kirsten

AU - Hasselbalch, Hans Carl

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2014/7

Y1 - 2014/7

N2 - YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

AB - YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.

U2 - 10.1016/j.leukres.2014.04.002

DO - 10.1016/j.leukres.2014.04.002

M3 - Journal article

VL - 38

SP - 816

EP - 821

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -

ID: 44378499